Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL
Status:
Not yet recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
This is a single-arm, single-center Phase II clinical trial for patients with relapsed or
refractory Peripheral T-cell lymphoma (PTCL). Immunotherapy with anti-PD-1 antibodies, such
as sintilimab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Chidamide and azacitidine may respectively
stop the growth of tumor cells by blocking histone deacetylation and DNA methylation enzymes
needed for cell growth. Giving chidamide and azacitidine with sintilimab these three drugs
may work better than single drug or combination of two drugs in treating patients with
relapsed or refractory peripheral T-cell lymphoma.